Skip to main content
Erschienen in: Cancer Cell International 1/2023

Open Access 01.12.2023 | Review

Circular RNAs in renal cell carcinoma: from mechanistic to clinical perspective

verfasst von: Chunjie Huang, Pooya Esfani Sarafraz, Parisa Enayati, Elham Mortazavi Mamaghani, Emad Babakhanzadeh, Majid Nazari

Erschienen in: Cancer Cell International | Ausgabe 1/2023

Abstract

CircRNAs, a special type of noncoding RNAs characterized by their stable structure and unique abilities to form backsplicing loops, have recently attracted the interest of scientists. These RNAs are abundant throughout the body and play important roles such as microRNA sponges, templates for transcription, and regulation of protein translation and RNA-binding proteins. Renal cancer development is highly correlated with abnormal circRNA expression in vivo. CircRNAs are currently considered promising targets for novel therapeutic approaches as well as possible biomarkers for prognosis and diagnosis of various malignancies. Despite our growing understanding of circRNA, numerous questions remain unanswered. Here, we address the characteristics of circRNAs and their function, focusing in particular on their impact on drug resistance, metabolic processes, metastasis, cell growth, and programmed cell death in renal cancer. In addition, the application of circRNAs as prognostic and diagnostic biomarkers will be discussed.
Hinweise
A correction to this article is available online at https://​doi.​org/​10.​1186/​s12935-023-03184-2.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

In 2020, kidney cancer led to nearly 180,000 new deaths worldwide, making it one of the most common cancers [1]. In the United States, it is the eighth most prevalent cancer, accounting for 4.2% of all new cancer diagnoses [2]. Renal cell carcinoma (RCC) is the most common subtype and accounts for between 60 and 80 percent of all primary renal malignancies [3]. Advanced RCC is associated with high morbidity and mortality, but recent advances in treatment have significantly improved the prognosis for RCC over the past decade [4]. In particular, immune checkpoint inhibitors (ICIs) has emerged as an effective and critical new approach in the treatment of kidney cancer [5, 6]. However, the growing evidence of the efficacy of these treatments must be weighed against their potential toxicity and the risks of overtreatment, especially as ICIs are now being studied in non-metastatic settings and in combination with other agents [7]. Therefore, the discovery of new biomarkers for tumors is an important and current clinical goal, and circRNAs have the potential to be valuable indicators of disease [8, 9].
Long-stranded noncoding RNAs (lncRNA, > 200 nt) and tiny RNAs, such as microRNA (miRNA), are two types of noncoding RNAs commonly categorized by size. Noncoding RNAs (ncRNAs) form a group of RNA that are not translated. Nevertheless, they play a critical role in various health conditions, particularly cancer [9]. Eukaryotes contain large numbers of CircRNAs, a class of naturally occurring long noncoding RNAs. In viroids, covalently closed CircRNAs were first found in 1976 [10]. They were later discovered to be present in the cytoplasm of eukaryotic cells, to have cell- and organ-specific expression, and to possess significant biological activities [11, 12]. As sequencing technology improved, the significance of circRNAs became more apparent. These specific lncRNAs harbor a distinctive covalent single-stranded closed loop arrangement without a 3ʹ poly(A) tail or 5ʹ cap, making them more durable than mRNAs and resistant to RNase A degradation [13]. CircRNAs exhibit dual roles in RCC, functioning as both oncogenes and tumor suppressors. Their primary mechanism of action involves acting as molecular sponges for microRNAs. CircRNAs control gene transcription, alternative splicing, and protein translation, act as microRNA sponges, and cooperate with RNA-binding proteins [14].
This review addresses the effects of circRNA production on the growth and progression of RCC and provides a basic overview of its principles. The capability of circRNAs as predictive and diagnostic biomarkers is also addressed. Future cancer therapies could benefit from the important insights and knowledge gained from a deeper understanding of circRNAs.

CircRNAs

Sanger began studying circRNAs in 1976 [15]. NcRNAs, previously considered “unique signals,” have received considerable attention as technology and knowledge have evolved. Because of their particular circular structure, circRNAs are more resilient to destruction by nucleic acid exonucleases than linear RNAs. The structure has remained largely unchanged throughout development and evolution.

Biogenesis of CircRNAs

The formation of circRNAs requires specific genomic features. Firstly, circRNA exons and their adjacent introns are notably long, averaging three times the length of canonical linear RNAs. Secondly, these extended introns must possess inverted complementary sequence elements, such as inverted repeat Alu elements, which facilitate the close proximity of downstream 5ʹ-donor and upstream 3ʹ-acceptor splice sites [16]. It is worth noting that the majority of circRNAs are found within protein-coding genes and consist of complete exons, suggesting that their transcription is mediated by RNA polymerase II. The majority of circRNAs, specifically 84%, are derived from protein-coding genes. Among these circRNAs, 85% align in the same sense direction as exons of both coding and non-coding genes, while 10% align in the opposite antisense direction. The remaining 5% of circRNAs align to untranslated regions, introns, or gene loci that have not been annotated [17]. CircRNAs formed through back-splicing, a process in which the 3ʹ splice site of a downstream exon is joined to the 5ʹ splice site of an upstream exon, creating a continuous loop structure. This differs from linear RNAs, which have 5ʹ caps and 3ʹ polyadenylated tails [16].
As a result of splicing of mRNA, precursor transfer RNAs (pre-tRNAs), intron circular RNAs (ciRNAs), exon circular RNAs (ecircRNAs), exon intron circular RNAs (eIcircRNAs), and tRNA intron circular RNAs (tricRNAs) are produced (Fig. 1). Most circRNAs are ecircRNAs, which are primarily placed in the cytoplasm. CiRNAs and EIcircRNAs, on the other hand, are mostly found in the nucleus. Standard models for circRNA loops include direct splicing back, lasso-driven circularization, and circularization mediated by RNA-binding proteins [14]. EcircRNAs are predominantly produced by direct backsplicing, a cleavage process in which a loop is formed in the precursor mRNA by covalently linking the upstream 3' splice acceptor site to the downstream 5ʹ splice donor site of the exon. This procedure creates a closed circRNA loop by generating a lariat splice loop, followed by shearing of the intron [18]. EIcircRNAs also apply the direct backsplicing method, but during backsplicing, some intron sequences are retained within the circRNA instead of being removed [19].
It is assumed that ciRNAs arise from the synthesis of lassos from introns deleted during splicing of the pre-mRNA. Synthesis of these ciRNAs can be amplified by expression vectors that rely on a consensus motif consisting of an 11 nucleotide C-rich component near the branch point and a 7 nucleotide GU-rich sequence near the 5ʹ splice site [20]. RNA-binding proteins (RBPs) contributed in circRNA formation include RNA-editing enzyme, muscle blinding protein 1, and fusion sarcoma protein [21, 22]. RBPs can dimerize and drive exon loops by binding to specific motifs in nearby introns [22]. Comprehensive transcriptome analyses revealed that 60% of human genes produce both linear and circular transcripts [23]. Canonical splice sites are used for circRNA biogenesis, and linear splicing of mRNAs competes with back-splicing. CircRNA transcription levels are often lower than mRNA transcription levels. Under normal physiological conditions, circRNA expression increases when backsplicing activity decreases and the efficiency of spliceosome components is reduced [24]. Exons in circular RNAs and the introns surrounding them are longer than those in linear RNAs. These elongated introns include inverted complementary sequence elements, for instance inverted Alu components, that promote the proximity of upstream 3-acceptor and downstream 5-donor splice sites [16].

CircRNA degradation and exosome release

Because of their unique circular structure, circRNAs are largely resistant to degradation. However, our understanding of the mechanisms by which they are degraded is still evolving. The mechanisms of circRNAs disintegration and extracellular vesicle discharge are summarized in Fig. 2. Certain circRNAs are degraded when they bind to miRNAs and are cleaved by Argonaute-2 (AGO2) [25]. Others are degraded by certain RNases after N6-methyladenosine (m6A) modification [26]. The core complex consisting of the N6 adenosine methyltransferase METTL3-METTL14 can make m6A modifications to circRNA transcripts, allowing cleavage by the YTHDF2-HRSP12-RNaseP/MRP complex in the cytoplasm [27].
Several decay mechanisms are linked to the secondary structures of circRNAs [28]. In cases where there is no viral infection, circRNA-RNA duplexes bind and hamper double-stranded RNA-activated protein kinase (PKR) due to ribonuclease L (RNase L) inactivity. RNase L cleaves circRNAs during viral infection, releasing and activating PKR, which is an important component of the initial innate immune response. Thus, activation of PKR is a direct consequence of circRNA degradation. Another degradation mechanism involves RBPs such as Ras GTPase-activating protein-binding protein 1 (G3BP1) and Regulator of Nonsense Transcripts 1 (UPF1) [29]. These RBPs bind circRNAs and unravel them, leading to their degradation, which is facilitated by the helicase activity of UPF1. This degradation depends on structure rather than RNA sequence.
When multivesicular endosomes fuse with the cell membrane, some circRNAs are packaged into tiny extracellular vesicles and released into the extracellular environment. [3032]. It is possible that these circRNAs are also unleashed as extracellular vesicles, but this needs further investigation [33]. Exosomes usually contain more circRNAs than the cells from which they are derived. Because exosomes can be detected in the kidney and are released throughout the nephron, it is reasonable to conclude that changes in circRNA concentration in exosomes detected in urine could provide important information about overall renal health [34]. Therefore, circRNAs in urine could serve as valuable noninvasive biomarkers of kidney disease.

Detection and identification of CircRNAs

Over 100,000 distinct circRNAs have been detected in human [35]. Their unique circular structure, lack of 3ʹ poly (A) tails and 5ʹ caps, and low abundance make detection by conventional methods difficult [36]. The first detections were made using Northern blotting and PCR methods [37]. Northern blotting, considered the gold standard, distinguishes circRNAs from linear RNAs by denaturing polyacrylamide gel electrophoresis and hybridization of RNA probes [16]. However, this technique suffers from low throughput and difficulties in detecting rare circRNAs [38]. RT -qPCR is commonly used for circRNA analysis but can produce misleading signals due to structural changes and rolling circle replication [39].
Newer techniques, such as rolling circle amplification (RCA), take advantage of the circular structure of circRNAs [40]. RCA offers simplicity, cost-effectiveness, and specificity in amplifying target circRNAs [41]. Enzyme-based detection reduces primer dependence by using duplex-specific nucleases (DSNs) to cleave DNA/circRNA hybrids, thereby enhancing fluorescence upon detection of the target circRNA [42]. NanoString Technologies’ nCounter assay allows accurate quantification of circRNA by hybridization with two probes. However, it requires expensive equipment [43]. Microarrays offer high-throughput detection but can pose problems when comparing data from different studies [44]. The subcellular localization of RNA can be determined by fluorescence in situ hybridization (FISH), which is, however, expensive and time-consuming [44, 45]. RNA-seq technology has greatly improved the identification of circRNAs [46]. However, circRNAs need to be biochemically enriched before short-read deep sequencing due to their low in vivo abundance and lack of poly (A) tails [47]. RiboRNA-seq provides valuable expression data but cannot differentiate signals from linear and circRNAs in exonic regions [48]. Small circRNAs can be detected using poly (A)-RNA-seq, but unusual circular isoforms cannot be precisely identified or quantified using this method [49]. RNase R-RNA-seq can improve circRNA enrichment compared with ribo-or poly (A)-RNA-seq [16]. Overall, an efficient, accurate, and sensitive method for circRNA research remains to be developed.

Functions of CircRNAs

MiRNA sponges

The role of circRNAs as miRNA sponges has been a major focus in research. An overview of functions of circRNAs has been displayed in Fig. 3. By binding to the 3ʹ-untranslated regions (3ʹUTR) of mRNA, miRNAs, a large class of small noncoding RNAs, can control gene expression and translation [50]. According to studies, circRNAs have the ability to bind to miRNAs and compete with mRNA for these interactions by serving as miRNA sponges and subtly influencing gene expression [51, 52]. This process increases mRNA production and subsequent protein translation [53]. CiRS-7, a well-studied circRNA, harbors over 70 miR-7 binding sites and reportedly binds to miR-139-3p, thereby promoting RCC progression and metastasis via the PI3K/AKT pathway [54]. Similarly, circEYA3 increases c-Myc expression by sequestering miR-1294, which leads to increased CDC42 expression and promotes the invasion and migration of clear cell renal cell carcinoma (ccRCC) [55]. CircFAT1 increases the expression of YES -associated protein 1 via its miR-375 binding sites, and its silencing decreases cell proliferation, migration and invasion [56]. CircRNA biogenesis competes with splicing of pre-mRNA and affects its expression. It depends on conventional splice sites and spliceosome mechanisms.
Research shows that circRNAs can regulate gene expression in various stages of different malignancies. EIcircRNAs enhance transcription of parental genes through interactions with the polymerase II complex and small nuclear U1 ribonucleoproteins (U1 snRNPs) [57]. CircDONSON activates the NURF complex to start the synthesis of SOX4, which promotes the growth of gastric cancer [58]. CircRHOT1 expression accelerates hepatocellular carcinoma (HCC) growth and metastasis by initiating NR2F6 transcription. Suppression of CircRHOT1 decreases proliferation and metastasis of hepatoma cells [59].

Interaction with proteins

Besides their role as miRNA sponges and interaction partners of polymerase II complexes, circRNAs also possess the ability to bind proteins [60]. In their function as protein sponges, circRNAs can indirectly modulate RNA, with certain circRNAs that have minimal miRNA-binding sites playing a critical role in protein binding. Interestingly, however, the binding of RBP to circular RNA is less tight than to linear mRNA [61]. CircFoxo3, for example, which is exceedingly expressed in noncancerous cells, is involved in cell cycle regulation [62]. It binds to P21 and CDK2 to form a ternary complex that inhibits cell cycle progression. Moreover, increased circAmotl1 expression in newborn cardiac tissue may enhance AKT activity and promote cardiomyocyte survival. As a result of circAmotl1 binding to PDK1, AKT, and AKT1 is phosphorylated and transported to the nucleus [63].

Translation of circRNAs

While circRNAs function as noncoding RNAs and typically lack the 5ʹ cap, 3ʹ poly (A) tail, or clear open reading frame (ORF) required for translational regulation, recent studies have shown that they can indeed code for proteins [64]. CircRNAs can not only bind proteins but also function as miRNA sponges and interacting parts of polymerase II complexes. This process is facilitated by a specific sequence that allows the incorporation of an artificial internal ribosome entry site (IRES) upstream of the start codon, which immediately initiates translation through the ribosome [65]. In addition, the presence of N6-methyladenosine (m6A)-methylated adenosine residues that bind directly to eIF3 has been shown to facilitate circRNA translation [64]. CircZNF609, a distinct regulator of myogenic cell proliferation, is a typical example. It features an ORF that has the same start codon as its linear equivalent and a stop codon in the ORF that is a product of backsplicing at the termination point. Association with heavy polysomes converts CircZNF609 into a protein in a manner that is both splice-dependent and cap-independent, shedding light on the occurrence of protein-coding circRNAs in eukaryotes [66]. In addition, Zhang and his team made a breakthrough discovery: circSHPRH is able to synthesize a new functional protein, SHPRH-146A, which plays an important role as a tumor suppressor in glioblastoma [67].

The role of circRNAs in RCC

CircRNAs are critical for the growth and progression of renal cancer. Through RNA-seq research, scientists have discovered about 2000 circRNAs that are differentially expressed in RCC [68]. These circRNAs are involved in a range of cellular functions in renal cells, such as cell proliferation, metastasis, epithelial-mesenchymal transition (EMT), apoptosis, and metabolism (Fig. 4). Table 1 provides most interesting reports of circRNAs in RCC. In the following section, we review how circRNAs regulate these cellular functions and the molecular causes underlying RCC.
Table 1
Interesting reports of circRNAs in RCC
CircRNA
Target miRNA
miRNA target gene/sponge
Expression
Function
Reference
Circ0005875
miR-502-5p
ETS1
Up
Cell Cycle( +)
Metastasis( +)
Apoptosis( −)
[69]
CircESRP1
miR-3942
CTCF
Down
Cell Cycle(-)
Metastasis(-)
[70]
CircCHST15
miR-125a-5p
EIF4EBP1
Up
Cell Cycle( +)
Metastasis( +)
[71]
CircSDHC
miR-127-3p
CDKN3/E2F1
Up
Cell Cycle( +)
Metastasis( +)
[72]
CircTLK1
miR-136-5p
CBX4
Up
Cell Cycle( +)
Metastasis( +)
[73]
CircMTO1
miR-9
LMX1A
Down
Cell Cycle(-)
Metastasis(-)
[74]
CircUBAP2
miR-148a-3p
FOXK2
Down
Cell Cycle(-)
Metastasis(-)
[75]
CircSCARB1
miR-510-5p
SDC3
Up
Cell Cycle( +)
Metastasis( +)
[76]
Circ0054537
miR- 130a-3p
cMET
Up
Cell Cycle( +)
Metastasis( +)
[66]
Circ0001368
miR-492
LATS2
Down
Cell Cycle(-)
Metastasis(-)
[77]
CircRAPGEF5
miR-27a-3p
TXNIP
Down
Cell Cycle(-)
Metastasis(-)
[78]
CircEGLN3
miR-1224-3p
HMGXB3
Up
Cell Cycle( +)
Metastasis( +)
[79]
Circ000926
miR-411
CDH2
Up
Cell Cycle( +)
Metastasis( +)
[80]
CircAKT3
miR-296-3p
E-cadherin
Down
Metastasis(-)
[81]
Circ0035483
miR-31-5p
HMGA1
UP
Glycolysis( +)
[82]
CircFOXP1
miR-423-5p
U2AF2
UP
Glycolysis( +)
[83]
Circ0054537
miR-640
NPTX2
UP
Glycolysis( +)
[84]
Circ0000069
miR-125a-5p
SLC1A5
UP
Cell Cycle( +)
Metastasis( +)
[85]

Cell cycle

Research suggests that dysregulated circRNA expression is associated with uncontrolled proliferation of renal cancer cells and interruption of cell cycle control. For example, increased circ000926 expression in renal cancer cells correlates with unfavorable patient outcome [80]. Suppression of Circ 000926 hinders xenograft growth and reduces renal cancer cell growth. By directly inhibiting miR-411, it serves as a miRNA sponge and enhances CDH2 expression. When CircEGLN3, which is overexpressed in renal cancer, is suppressed, proliferation of ACHN and 769-P renal cancer cells is reduced [79]. CircEGNL3 functions as a miRNA sponge for miR-1224-3p, which consequently increases the expression of HMGXB3, decreases the inhibitory effect of miR-1224-3p on renal cancer, and promotes cell cycle and metastasis. In separate studies, circSCARB1 levels were shown to be increased in various RCC cell lines and RCC tissue [76]. CircSCARB1 interaction with miR-510-5p and SDC3 (a miR-510-5p target) facilitates cell growth inhibition caused by circSCARB1 silencing.
Simultaneous transfection with SDC3 partially counteracts the regulation of cell proliferation, whereas transfection with a miR-510-5p mimic decreases both SDC3 expression and cellular expansion. Moreover, overexpression of circMTO1 reduces the growth of 786-O and A498 renal cancer cells, whereas suppression of circMTO1 accelerates the development of OS-RC-2 and SN12C renal cancer cells [74]. MiR-223 and miR-9 are absorbed by circMTO1, which decreases their levels. Inhibition of circMTO1 promotes RCC cell growth by reducing LMX1A, a target of miR-9. MiR-9 has been shown to control LMX1A expression in RCC by transfection with a miR-9 mimic. Overexpression of a miR-9 inhibitor and LMX1A counteracts the tumour-promoting effect of circMTO1 silencing. Similarly, circTLK1 was discovered as a novel circRNA candidate formed by the TLK1 gene by high-throughput sequencing of circRNAs in renal cancer cell lines [73]. RCC cells have high expression of CircTLK1, and its silencing inhibits RCC cell growth. RCC patients with advanced TNM stage and high circSDHC expression in tissues detected by GSE100186 and GSE137836 sequencing have a poor prognosis [72]. In vivo and in vitro and, circSDHC promotes tumor cell proliferation.
Competition between circSDHC and miR-127-3p for binding was demonstrated using luciferase reporter assays and RNA pulldown to prevent suppression of E2F1 and CDKN3 signaling pathways leading to metastasis of RCC. When circSDHC expression is reduced, CDKN3 expression also decreases, suppressing E2F1 signaling, which can be restored by using a miR-127-3p inhibitor. CirCHT15 has been shown to be an accurate predictor of both overall survival (OS) and progression-free survival (PFS) after surgical resection of ccRCC [72]. Both renal cancer cell lines and ccRCC tissues show significant expression level of CirCHT15. Data from in vivo and in vitro experiments propose that CirCHT15 is a factor in the growth of ccRCC cells. CirCHT15 controls EIF4EBP1 expression through direct interaction with miR-125a-5p. CircDVL1 is not positively associated to the malignant characteristics of ccRCC and is expressed at low levels in sera and tissues of ccRCC cases [86]. Overexpression of circDVL1, which also leads to arrest of G1/S phase, prevents proliferation of many ccRCC cells. In ccRCC cells, circDVL1 acts as a miRNA sponge for oncogenic miR-412-3p and blocks its ability to inhibit PCDH7.

Metastasis and EMT

Cancer cell invasion and metastasis, two crucial processes in the development and progression of renal cancer, have been found to be regulated by circRNAs [87]. Thus, a possible link between reduced circPSD3 levels and tumor metastasis in ccRCC patients is suggested by a decrease in circPSD3 expression in ccRCC tissues [88]. CircPSD3 significantly reduces cell invasion, migration and EMT under laboratory conditions and prevents lung metastasis in animal models. CircPSD3 and miRNA-25-3p interact in regulating FBXW7 expression. CircPSD3 serves as a potential target for the diagnosis and treatment of ccRCC by blocking the miR-25-3p/FBXW7 pathway, thereby arresting tumor growth. Despite uncertainty about circRAPGEF5 role in RCC, a study with data from 245 patients with this disease found a favorable correlation between aggressive clinical features and decreased circRAPGEF5 expression [78]. The circRAPGEF5/miR-27a-3p/TXNIP pathway was observed to inhibit RCC growth and progression. In ACHN, 786-O, and A498 cell lines and RCC tissues, one study discovered that circ0001368 expression was reduced [77].
The findings indicate that circ0001368 targets miR-492 which directly effects LATS2 by binding to the 3ʹUTR region of LATS2. Overexpression of miR-492 promoted cell invasion, while suppression of miR-492 inhibited it. Prior studies have shown that LATS2 attenuates hepatocellular carcinoma via the DNMT1/EZH2 pathway and reduces metastasis of glioma cell by enhancing tafazzin [77]. Overexpression of LATS2 dramatically reduces the ability of ACHN and 786-O cells to proliferate and invade. By scavenging miR-492, circ0001368 increases LATS2 expression while reducing growth and invasion of renal cancer cells. Furthermore, the circSCARB1/miR-510-5p/SDC3 signaling pathway facilitates renal carcinoma cell invasion and migration [76]. In vivo and in vitro studies have shown that circUBAP2 expression is significantly reduced in ccRCC [75]. Significant reduction in ccRCC cell invasion and migration is achieved by increased circUBAP2 expression. MiR-148a-3p counteracts the inhibitory effect of CircUBAP2 on ccRCC cell invasion and migration. CircUBAP2 serves as miRNA sponge for miR-148a-3p. Moreover, the miR-148a-3p target gene FOXK2 has been shown to suppress ccRCC cells by reversing the effect of miR-148a-3p inhibitor [75]. Moreover, circUBAP2 controls the miR-148a-3p/FOXK2 pathway to significantly limit tumor growth in ccRCC cells [75]. In ccRCC, circAKT3 was consistently downregulated. Sequencing of 60 ccRCC tissues, surrounding normal tissues, ccRCC cell lines, and another 60 tissue samples led to this discovery [81]. Overexpression of circAKT3 prevented ccRCC metastasis, whereas knockdown of circAKT3 stimulated ccRCC invasion and migration. The miR-296-3p/E-cadherin signaling pathway is blocked by circAKT3, which prevents the spread of ccRCC.
According to one study, circTLK1 is mainly present in the cytoplasm, and high expression positively correlates with distant metastases and poor prognosis for patients. MiR-136-5p sponging positively controls expression of CBX4 [73]. The suppression of RCC cell phenotype by prevention of circTLK1 is reversed by increased CBX4 expression. Moreover, there is a positive association between the expression level of VEGFA and CBX4 in RCC tissues. Significantly less VEGFA was expressed in RCC cells when CBX4 was knocked down. In another study, circESRP1 expression was shown to be low in renal cancer cells and tissues and was negatively related with tumor size, TNM stage, and distant metastasis of renal cancer [70]. CircESRP1 interacts with miR-3942 in a competitive manner that controls CTCF downstream. CTCF specifically enhances transcription of circESRP1, modulates the circESRP1/miR-3942 axis, and forms a positive feedback loop. By c-Myc-driven EMT, this signaling system controls the behavior of ccRCC cells. CircMYLK, which is particularly upregulated in RCC, associates with miR-513a-5p and promotes VEGFC production, facilitating tumorigenesis of RCC cells [89]. Metastasis of RCC is stopped by silencing circMYLK both under laboratory conditions and in animal models. Upregulation of circTXNDC11 is associated with advanced TNM stage and lymph node metastasis in RCC. Inhibition of circTXNDC11 slows cell invasion and metastasis under laboratory conditions [90]. By stimulating the MAPK/ERK pathway, CircTXNDC11 promotes RCC invasion and migration.

Apoptosis

In renal cancer cells, circRNAs were discovered to have an effect on apoptosis. Increase in miR-130a-3p expression promotes RCC cell death because it is abnormally low in RCC cells [91]. Luciferase reporter assays and RNA pulldown proved that miR-130a-3p and circ0054537 directly interact. Circ0054537 and miR-130a-3p work together to control the oncogene c-Met, which is suppressed by miR-130a-3p and affects the development and spread of RCC tumors. Similarly, significant circSCARB1 expression was found in RCC cells, and knockdown of circSCARB1 causes apoptosis in A498 and 786-O cell lines [91]. Increased expression of Circ0005875 was observed in RCC. When this circular RNA is knocked down, the expression of miR-502-5p increases, leading to higher apoptosis propensity in renal cancer cells [69]. Sequencing revealed high circEGLN3 levels in RCC tissues and cell lines, indicating a negative prognosis for RCC patients [92]. RCC cells undergo apoptosis when CircEGLN3 is silenced. CircEGLN3, which is mainly placed in the cytoplasm, blocks RCC development by targeting miR-1299, which alters IRF7 level. Circ001842 is also overexpressed in RCC and contributes to disease development via an SLC39A14-dependent miR-502-5p pathway [93]. When circ001842 is silenced, RCC cells are driven into apoptosis. In another study, circNUP98 was found to be preferentially increased in 78 paired RCC tumors compared to nearby normal tissues. Inhibition of circNUP98 increased miR-567 expression, slowed RCC cell growth, and decreased PRDX3 levels [94]. In addition, STAT3 was found to promote circNUP98 in RCC cells. The new STAT3/circNUP98/miR-567/PRDX3 pathway exploits the CircNUP98 oncogene as a therapeutic target and possible biomarker for the treatment of RCC.

Metabolism

CircRNAs have been displayed to control the metabolism of renal carcinoma cells. Circ0035483, for example, is overexpressed in renal cancer cells and tissues. Circ0035483 overexpression can promote glycolytic metabolism in RCC cells, as shown by the fact that a decrease in Circ0035483 expression reduces lactate production and glucose consumption in RCC cells [94]. In RCC cells, circ0035483 is turned off when miR-31-5p is overexpressed. By negatively regulating HMGA1, miR-31-5p inhibits the ability of RCC cells to become malignant. Due to the high expression of circFOXP1 in RCC tissues and cell lines, downregulation of circFOXP1 inhibits glycolysis in renal cancer cells [83]. The miR-423-5p/U2AF2 pathway is activated by ZNF263, which is upstream of circFOXP1 and promotes renal carcinoma development. According to this study, RCC tissues and cells had higher levels of circ0054537, which was mainly found in the cytoplasm [84]. Glycolysis is inhibited and apoptosis is promoted in RCC cells when the circ0054537 gene is knocked down. Circ0054537 attaches to miR-640 and targets NPTX2, as demonstrated by luciferase reporter.
Yang and colleagues reported that the level of circ0000069 was abnormally high in RCC tissues and cells. Reduction of circ0000069 led to a decrease in proliferation, metastasis, and glutamine metabolism of RCC cells [85]. In addition, circ0000069 was found to act as a sponge for miR-125a-5p, and inhibition of miR-125a-5p mitigated the impacts of circ0000069 reduction on the malignant behavior of RCC cells. The study also identified SLC1A5 as a target gene of miR-125a-5p. Higher expression of miR-125a-5p suppressed RCC cell progression, whereas increasing SLC1A5 counteracted this effect.

Clinical application of circRNAs

Numerous studies have recognized the diagnostic capability clinical relevance of circRNAs expression in RCC. For instance, circ0001451 was highlighted for its promising diagnostic marker for ccRCC with an area under the receiver operating characteristic curve (AUC-ROC) of 0.70, complemented by a specificity of 0.60 and sensitivity of 0.75 [95]. CircHIPK3 was also identified as a potential diagnostic marker and has a remarkable AUC of 0.95 for ccRCC [96]. In addition, research suggests that the combination of circRNAs with linear transcripts may provide greater diagnostic value compared to single circRNAs. For example, Franz et al. identified circNOX4, circEGLN3, and circRHOBTB3 as potential diagnostic biomarkers. The AUC-ROC values of circRHOBTB3 and circNOX4 and in RCC tissues were 0.82 and 0.81, respectively [97]. However, circEGLN3 displayed higher reliability with an AUC-ROC of 0.98. More impressively, simultaneous detection of linEGLN3 and circEGLN3 resulted in an improved AUC-ROC of 0.99, corresponding to a sensitivity of 95% and a specificity of 99%. A meta-analysis by Rashedi et al. evaluated 8 studies with 604 RCC cases and 527 controls to investigate the diagnostic value of circRNAs for RCC detection. The results showed that circRNAs have the potential to be used as diagnostic biomarkers for RCC tissue samples, with a pooled sensitivity, specificity, and AUC of 0.84, 0.84, and 0.91, respectively. This suggests that circRNAs are highly accurate in detecting RCC in tissue samples. However, the accuracy of circRNAs as diagnostic biomarkers for body fluid (serum and urine) specimens was moderate, with a sensitivity, specificity, and AUC of 0.78, 0.69, and 0.71, respectively. This suggests that circRNAs are less accurate in detecting RCC in body fluid samples [98].
Certain circRNAs have been shown to be important prognostic biomarkers, influencing outcomes such as OS, DFS, and PFS. Li et al. reported that increased circPRRC2A expression was a distinct risk factor for decreased OS and metastasis-free survival [99]. It was also found that patients with RCC who have increased expression of circTLK1 [73], circNUP98 [94], and circ0085576 [100] have reduced OS and DFS rates. On the other hand, lower expression of circRAPGEF5 has been correlated with unfavorable OS and RFS in patients with RCC [78]. In addition, Frey et al. found that low circNETO2 and high circEHD2 levels independently predicted a decline in PFS, OS, and cancer-specific survival in patients with ccRCC undertaking nephrectomy [101]. In addition, it was observed that patients with ccRCC who had higher circ101341 and circ-ABCB10 expression showed worse OS than patients with lower expressions [102]. Similarly, Zeng et al. reported lower survival rates in patients with high circ001842 expression, suggesting a positive correlation with RCC severity [93]. Interestingly, circEHD2 is highly expressed in ccRCC tissues but rarely detected in normal adjacent kidney tissues that it may be a specific biomarker for prognosis of ccRCC patients. High circEHD2 levels are an independent prognostic factor for OS and PFS in patients with ccRCC [103]. A recent meta-analysis found that tumor promoter circRNAs were associated with reduced OS, while tumor suppressor circRNAs were linked with better OS in RCC patients. These results were consistent in the multivariate analysis. Similar findings were obtained for DFS/PFS/RFS, with tumor promoter circRNAs being correlated with poor DFS/PFS/RFS and tumor suppressor circRNAs being associated with improved DFS/PFS/RFS in the univariate analysis. These findings were also consistent in the multivariate analysis [98].
In a microarray study of ccRCC tissue, a circRNA signature involving circNOX4, circRHOBTB3, and circEGLN3 was identified as a potential prognostic biomarker for cancer-specific, recurrence-free, and overall survival, with a reference of [104]. This signature demonstrated improved predictive accuracy compared to clinical models based on clinicopathological factors. Notably, the expression of circEGLN3 showed a high accuracy of 97% in discriminating between malignant and normal tissue. Another study reported that increased expression of circEGLN3 was associated with shorter survival in patients with RCC, with a reference of [39]. In patients with ccRCC, the circRNA circ-ABCB10 was found to be upregulated in tumor tissues compared to adjacent tissues. High expression of circ-ABCB10 correlated with advanced pathological grade and TNM stage and served as an independent predictor of worse overall survival in these patients, with a reference of [105]. Furthermore, mRNA expression of METTL14 was found to negatively correlate with TNM stage and positively correlate with overall survival in patients with RCC, with a reference of [106]. Rashedi et al. analyzed 26 studies with a total of 2048 patients with RCC and found that 6 circRNAs were downregulated and 18 circRNAs were upregulated in RCC tissues. The downregulated circRNAs were associated with smaller tumor size, lower T stage, less lymph node metastasis, less distant metastasis, and lower TNM stage. The upregulated circRNAs were correlated with higher T stage, more lymph node metastasis, more distant metastasis, and higher TNM stage [98].
The problem of drug resistance is currently a major challenge in cancer therapy and requires urgent attention [107]. Circsnx6, a particular circular RNA, is particularly abundantly expressed in sunitinib-resistant RCC cells [108]. It is thought to play a role in sunitinib resistance by modulating the level of lysophosphatidic acid within cells. Since CircSNX6 interacts with the U1 snRNP to upregulate ME1 expression and induce drug resistance in RCCs, CircME1 could be used as a biomarker to predict sunitinib resistance and as a therapeutic target for ccRCC [109]. Gemcitabine resistance in RCC and the high expression level of circ0035483 are associated [110]. Gemcitabine, a chemotherapeutic agent that is a deoxycytidine nucleoside analog, shows remarkable therapeutic efficacy against RCC. However, drug resistance is often a major problem. Overexpression of circ0035483 has been found to stimulate gemcitabine resistance by increasing cyclin B1 expression by sequestering miR-335 in RCC [110]. In addition, reduced expression of circ0035483 was found to inhibit cellular glycolytic activity [82]. Increased glycolytic activity is a common feature of proliferating cells and is often targeted in renal cancer therapies. Therefore, circ0035483 has the potential to circumvent gemcitabine resistance and affect glycolytic activity in RCC treatment. Nevertheless, our knowledge of the role and mechanisms of circRNAs in the development of anticancer drug resistance is still at an early stage and remains to be fully explored.
One potential therapeutic approach involves modulating native pathogenic circRNAs through methods such as silencing or overexpression by artificial circRNAs. These artificial circRNAs can be engineered to act as miRNA sponges, generate circular versions of native linear RNAs with therapeutic effects, translate proteins, modulate the immune system, control protein activity (as aptamers), control transcription or splicing, and replicate autonomously following in vivo delivery [111]. Silencing circRNAs, such as apoptosis-related circRNA (circHIPK3), circFoxo3, and cZNF609, mitochondrialfission, and using short hairpin RNA has shown beneficial effects in various disease models [111]. The CRISPR-Cas genome editing system has also been used to generate a mouse model with knockout of ciRs-7 [112]. Other approaches to silencing circRNAs include using antisense oligonucleotides (AONs) that bind to circRNAs and inhibit their interactions with target molecules, as well as antagonists that block the molecular interactions of circRNAs by shielding binding sites for proteins or miRNAs [113]. On the other hand, overexpression of circRNAs can be achieved by packaging them into extracellular vesicles for use as delivery vectors or by injecting an expression plasmid conjugated with colloidal gold nanoparticles, as demonstrated for circFoxo3 [114].
Nanoparticles have emerged as potential delivery systems for circRNA-based therapeutics, offering advantages such as improved stability, enhanced intracellular entry, and reduced immunogenicity of these molecules. In a mouse study, gold nanoparticles (PEG-AuNPs) conjugated with short interfering RNA (siRNA) targeting circDnmt1 demonstrated the ability to effectively suppress tumor growth and cellular autophagy [115]. Another study revealed that using AuNPs to deliver AONs, which block the binding sites on circCcnb1 for Ccnb1 and Cdk1, resulted in inhibited tumor growth and increased mouse survival [116]. These findings highlight the potential of nanoparticles as promising delivery systems for circRNA-targeting agents in renal cancer. In addition to nanoparticles, exosomes have also been investigated as carriers for circRNA-based therapeutics and circRNA expression vectors. Exosomes, small vesicles secreted by cells, contain various biomolecules including circRNAs. They play a crucial role in intercellular communication and can be engineered to deliver therapeutic molecules to specific target cells. However, further research is necessary to optimize the properties of nanoparticles and exosomes to ensure efficient and effective delivery of circRNA-based therapeutics in the context of renal cancer [24].
Therapeutic approaches utilizing circRNAs have primarily been investigated in preclinical studies. However, several challenges must be addressed before fully realizing the therapeutic potential of these approaches [117]. One significant concern with RNA interference (RNAi)-based strategies is the potential for off-target gene silencing, similar to the miRNA-like effect induced by small molecules like siRNA. The targeting of transcripts by siRNA relies on partial complementarity, typically occurring between the 3ʹ UTR of the transcript and the seed region of the siRNA [118]. While circRNA knockdown experiments often confirm that corresponding linear mRNA levels remain unaffected, off-target effects beyond their linear counterparts are less predictable. Ongoing research focuses on designing siRNA molecules to mitigate off-target effects in RNAi approaches [119]. It is important to note that while many circRNAs exhibit tissue- or cell-specific expression patterns, some circRNAs are present in multiple tissue or cell types, posing challenges when employing common targeting strategies that may inadvertently affect off-target tissues or cells [120]. Another consideration is the safety of using PEG as vehicles for delivering circRNA-targeting agents or circRNA plasmids in animal models, as their potential clinical use remains uncertain due to inconsistent conclusions regarding their toxicity from previous studies [121]. While there is significant interest in applying circRNA research findings to clinical scenarios for early disease diagnosis and prognosis prediction, it is essential to conduct large-scale clinical studies to validate the reliability and sensitivity of these circRNA biomarkers.

Conclusions

To thoroughly evaluate the therapeutic potential of circRNAs in RCC, further research is needed, including multicenter validation and larger sample size. The discovery of additional circRNAs and the elucidation of their biological functions and mechanisms are critical for the development of efficient therapeutic approaches. Challenges in circRNA therapy include improving vectors, cyclization techniques, delivery methods, chemical synthesis, and control methods. Advanced technologies such as CRISPR-Cas-based editing and single-cell RNA-Seq will further our understanding of circRNAs and their clinical utility. Despite these gaps in understanding, circRNAs are a promising tool for clinical diagnosis and treatment. This article reviews the biosynthesis, regulation, identification techniques, and role of circRNAs in renal cancer, including their effects on drug resistance, metabolism, apoptosis, tumor growth, and metastasis. Recent advancements have identified critical circRNAs in urologic malignancies, making circRNA-based tumor diagnosis and treatment attractive.

Acknowledgements

Not applicable.

Declarations

Not applicable.
All authors reviewed the paper and agreed upon its publication.

Competing interests

The authors have no potential conflicts of interest to declare.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Zurück zum Zitat Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.PubMedCrossRef Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.PubMedCrossRef
3.
Zurück zum Zitat Elbe N, Sauter G, Epstein J. Pathology and genetics of tumours of the urinary system and male genital organs: international agency for research on cancer (IARC). Oxford: Oxford University Press; 2004. Elbe N, Sauter G, Epstein J. Pathology and genetics of tumours of the urinary system and male genital organs: international agency for research on cancer (IARC). Oxford: Oxford University Press; 2004.
4.
Zurück zum Zitat Singh D. Current updates and future perspectives on the management of renal cell carcinoma. Life Sci. 2021;264:118632.PubMedCrossRef Singh D. Current updates and future perspectives on the management of renal cell carcinoma. Life Sci. 2021;264:118632.PubMedCrossRef
5.
Zurück zum Zitat Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404–15.PubMedCrossRef Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404–15.PubMedCrossRef
6.
Zurück zum Zitat Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–15.PubMedPubMedCentralCrossRef Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–15.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Larroquette M, Peyraud F, Domblides C, Lefort F, Bernhard J-C, Ravaud A, et al. Adjuvant therapy in renal cell carcinoma: current knowledges and future perspectives. Cancer Treat Rev. 2021;97:102207.PubMedCrossRef Larroquette M, Peyraud F, Domblides C, Lefort F, Bernhard J-C, Ravaud A, et al. Adjuvant therapy in renal cell carcinoma: current knowledges and future perspectives. Cancer Treat Rev. 2021;97:102207.PubMedCrossRef
8.
Zurück zum Zitat Xie Y, Yuan X, Zhou W, Kosiba AA, Shi H, Gu J, et al. The circular RNA HIPK3 (circHIPK3) and its regulation in cancer progression: Review. Life Sci. 2020;254:117252.PubMedCrossRef Xie Y, Yuan X, Zhou W, Kosiba AA, Shi H, Gu J, et al. The circular RNA HIPK3 (circHIPK3) and its regulation in cancer progression: Review. Life Sci. 2020;254:117252.PubMedCrossRef
9.
Zurück zum Zitat Di X, Jin X, Li R, Zhao M, Wang K. CircRNAs and lung cancer: biomarkers and master regulators. Life Sci. 2019;220:177–85.PubMedCrossRef Di X, Jin X, Li R, Zhao M, Wang K. CircRNAs and lung cancer: biomarkers and master regulators. Life Sci. 2019;220:177–85.PubMedCrossRef
10.
Zurück zum Zitat Sanger HL, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci. 1976;73(11):3852–6.PubMedPubMedCentralCrossRef Sanger HL, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci. 1976;73(11):3852–6.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Hsu M-T, Coca-Prados M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature. 1979;280:339–40.PubMedCrossRef Hsu M-T, Coca-Prados M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature. 1979;280:339–40.PubMedCrossRef
12.
Zurück zum Zitat van Zonneveld AJ, Kölling M, Bijkerk R, Lorenzen JM. Circular RNAs in kidney disease and cancer. Nat Rev Nephrol. 2021;17(12):814–26.PubMedCrossRef van Zonneveld AJ, Kölling M, Bijkerk R, Lorenzen JM. Circular RNAs in kidney disease and cancer. Nat Rev Nephrol. 2021;17(12):814–26.PubMedCrossRef
13.
Zurück zum Zitat Wang Y, Zhang Y, Wang P, Fu X, Lin W. Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy. Mol Cancer. 2020;19(1):1–10.CrossRef Wang Y, Zhang Y, Wang P, Fu X, Lin W. Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy. Mol Cancer. 2020;19(1):1–10.CrossRef
15.
Zurück zum Zitat Szoka F Jr, Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng. 1980;9(1):467–508.PubMedCrossRef Szoka F Jr, Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng. 1980;9(1):467–508.PubMedCrossRef
16.
Zurück zum Zitat Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333–8.PubMedCrossRef Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333–8.PubMedCrossRef
17.
Zurück zum Zitat Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS ONE. 2012;7(2):e30733.PubMedPubMedCentralCrossRef Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS ONE. 2012;7(2):e30733.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Zhang Z-h, Wang Y, Zhang Y, Zheng S-F, Feng T, Tian X, et al. The function and mechanisms of action of circular RNAs in urologic cancer. Mol cancer. 2023;22(1):61.PubMedPubMedCentralCrossRef Zhang Z-h, Wang Y, Zhang Y, Zheng S-F, Feng T, Tian X, et al. The function and mechanisms of action of circular RNAs in urologic cancer. Mol cancer. 2023;22(1):61.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Zhang Y, Zhang X-O, Chen T, Xiang J-F, Yin Q-F, Xing Y-H, et al. Circular intronic long noncoding RNAs. Mol Cell. 2013;51(6):792–806.PubMedCrossRef Zhang Y, Zhang X-O, Chen T, Xiang J-F, Yin Q-F, Xing Y-H, et al. Circular intronic long noncoding RNAs. Mol Cell. 2013;51(6):792–806.PubMedCrossRef
21.
Zurück zum Zitat Itskovich SS, Gurunathan A, Clark J, Burwinkel M, Wunderlich M, Berger MR, et al. MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia. Nat Commun. 2020;11(1):2369.PubMedPubMedCentralCrossRef Itskovich SS, Gurunathan A, Clark J, Burwinkel M, Wunderlich M, Berger MR, et al. MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia. Nat Commun. 2020;11(1):2369.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Conn SJ, Katherine AP, John Toubia Conn VM, Salmanidis M, Phillips CA, Roslan S, Schreiber AW, Gregory PA, Goodall GJ. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160(6):1125–34.PubMedCrossRef Conn SJ, Katherine AP, John Toubia Conn VM, Salmanidis M, Phillips CA, Roslan S, Schreiber AW, Gregory PA, Goodall GJ. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160(6):1125–34.PubMedCrossRef
23.
24.
Zurück zum Zitat He AT, Liu J, Li F, Yang BB. Targeting circular RNAs as a therapeutic approach: current strategies and challenges. Signal Transduct Target Ther. 2021;6(1):185.PubMedPubMedCentralCrossRef He AT, Liu J, Li F, Yang BB. Targeting circular RNAs as a therapeutic approach: current strategies and challenges. Signal Transduct Target Ther. 2021;6(1):185.PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Hansen TB, Wiklund ED, Bramsen JB, Villadsen SB, Statham AL, Clark SJ, et al. miRNA-dependent gene silencing involving Ago2-mediated cleavage of a circular antisense RNA. Embo j. 2011;30(21):4414–22.PubMedPubMedCentralCrossRef Hansen TB, Wiklund ED, Bramsen JB, Villadsen SB, Statham AL, Clark SJ, et al. miRNA-dependent gene silencing involving Ago2-mediated cleavage of a circular antisense RNA. Embo j. 2011;30(21):4414–22.PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Park OH, Ha H, Lee Y, Boo SH, Kwon DH, Song HK, et al. Endoribonucleolytic cleavage of m(6)A-containing RNAs by RNase P/MRP complex. Mol Cell. 2019;74(3):494-507.e8.PubMedCrossRef Park OH, Ha H, Lee Y, Boo SH, Kwon DH, Song HK, et al. Endoribonucleolytic cleavage of m(6)A-containing RNAs by RNase P/MRP complex. Mol Cell. 2019;74(3):494-507.e8.PubMedCrossRef
27.
Zurück zum Zitat Lee Y, Choe J, Park OH, Kim YK. Molecular mechanisms driving mRNA degradation by m(6)A modification. Trends Genet TIG. 2020;36(3):177–88.PubMedCrossRef Lee Y, Choe J, Park OH, Kim YK. Molecular mechanisms driving mRNA degradation by m(6)A modification. Trends Genet TIG. 2020;36(3):177–88.PubMedCrossRef
28.
Zurück zum Zitat Liu CX, Li X, Nan F, Jiang S, Gao X, Guo SK, et al. Structure and degradation of circular RNAs regulate PKR activation in innate immunity. Cell. 2019;177(4):865-80.e21.PubMedCrossRef Liu CX, Li X, Nan F, Jiang S, Gao X, Guo SK, et al. Structure and degradation of circular RNAs regulate PKR activation in innate immunity. Cell. 2019;177(4):865-80.e21.PubMedCrossRef
30.
Zurück zum Zitat Preußer C, Hung LH, Schneider T, Schreiner S, Hardt M, Moebus A, et al. Selective release of circRNAs in platelet-derived extracellular vesicles. J Extracell Vesicles. 2018;7(1):1424473.PubMedPubMedCentralCrossRef Preußer C, Hung LH, Schneider T, Schreiner S, Hardt M, Moebus A, et al. Selective release of circRNAs in platelet-derived extracellular vesicles. J Extracell Vesicles. 2018;7(1):1424473.PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Lasda E, Parker R. Circular RNAs co-precipitate with extracellular vesicles: a possible mechanism for circRNA clearance. PLoS ONE. 2016;11(2):e0148407.PubMedPubMedCentralCrossRef Lasda E, Parker R. Circular RNAs co-precipitate with extracellular vesicles: a possible mechanism for circRNA clearance. PLoS ONE. 2016;11(2):e0148407.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Memczak S, Papavasileiou P, Peters O, Rajewsky N. Identification and characterization of circular RNAs as a new class of putative biomarkers in human blood. PLoS ONE. 2015;10(10):e0141214.PubMedPubMedCentralCrossRef Memczak S, Papavasileiou P, Peters O, Rajewsky N. Identification and characterization of circular RNAs as a new class of putative biomarkers in human blood. PLoS ONE. 2015;10(10):e0141214.PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat van Balkom BW, Pisitkun T, Verhaar MC, Knepper MA. Exosomes and the kidney: prospects for diagnosis and therapy of renal diseases. Kidney Int. 2011;80(11):1138–45.PubMedPubMedCentralCrossRef van Balkom BW, Pisitkun T, Verhaar MC, Knepper MA. Exosomes and the kidney: prospects for diagnosis and therapy of renal diseases. Kidney Int. 2011;80(11):1138–45.PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Ma X-K, Xue W, Chen L-L, Yang L. CIRCexplorer pipelines for circRNA annotation and quantification from non-polyadenylated RNA-seq datasets. Methods. 2021;196:3–10.PubMedCrossRef Ma X-K, Xue W, Chen L-L, Yang L. CIRCexplorer pipelines for circRNA annotation and quantification from non-polyadenylated RNA-seq datasets. Methods. 2021;196:3–10.PubMedCrossRef
37.
Zurück zum Zitat Mi Z, Zhongqiang C, Caiyun J, Yanan L, Jianhua W, Liang L. Circular RNA detection methods: a minireview. Talanta. 2022;238:123066.PubMedCrossRef Mi Z, Zhongqiang C, Caiyun J, Yanan L, Jianhua W, Liang L. Circular RNA detection methods: a minireview. Talanta. 2022;238:123066.PubMedCrossRef
38.
Zurück zum Zitat D’Ambra E, Morlando M. Study of circular RNA expression by nonradioactive northern blot procedure. In: Navarro A, editor. Long non-coding RNAs in cancer. New York: Springer; 2021. p. 371–83.CrossRef D’Ambra E, Morlando M. Study of circular RNA expression by nonradioactive northern blot procedure. In: Navarro A, editor. Long non-coding RNAs in cancer. New York: Springer; 2021. p. 371–83.CrossRef
39.
Zurück zum Zitat Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19(2):141–57.PubMedPubMedCentralCrossRef Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19(2):141–57.PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Lin C, Xiao Z, Zhang X, Wu G. In situ hybridization assay for circular RNA visualization based on padlock probe and rolling circle amplification. Biochem Biophys Res Commun. 2022;610:30–4.PubMedCrossRef Lin C, Xiao Z, Zhang X, Wu G. In situ hybridization assay for circular RNA visualization based on padlock probe and rolling circle amplification. Biochem Biophys Res Commun. 2022;610:30–4.PubMedCrossRef
41.
Zurück zum Zitat Liu Y, Zhang X, Liu M, Xu F, Zhang Q, Zhang Y, et al. Direct detection of circRNA in real samples using reverse transcription-rolling circle amplification. Anal Chim Acta. 2020;1101:169–75.PubMedCrossRef Liu Y, Zhang X, Liu M, Xu F, Zhang Q, Zhang Y, et al. Direct detection of circRNA in real samples using reverse transcription-rolling circle amplification. Anal Chim Acta. 2020;1101:169–75.PubMedCrossRef
42.
Zurück zum Zitat Jiao J, Gao T, Shi H, Sheng A, Xiang Y, Shu Y, et al. A method to directly assay circRNA in real samples. Chem Commun. 2018;54(95):13451–4.CrossRef Jiao J, Gao T, Shi H, Sheng A, Xiang Y, Shu Y, et al. A method to directly assay circRNA in real samples. Chem Commun. 2018;54(95):13451–4.CrossRef
43.
Zurück zum Zitat Dahl M, Daugaard I, Andersen MS, Hansen TB, Grønbæk K, Kjems J, et al. Enzyme-free digital counting of endogenous circular RNA molecules in B-cell malignancies. Lab Invest. 2018;98(12):1657–69.PubMedPubMedCentralCrossRef Dahl M, Daugaard I, Andersen MS, Hansen TB, Grønbæk K, Kjems J, et al. Enzyme-free digital counting of endogenous circular RNA molecules in B-cell malignancies. Lab Invest. 2018;98(12):1657–69.PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Tang Q, Chen Z, Zhao L, Xu H. Circular RNA hsa_circ_0000515 acts as a miR-326 sponge to promote cervical cancer progression through up-regulation of ELK1. Aging. 2019;11(22):9982–99.PubMedPubMedCentralCrossRef Tang Q, Chen Z, Zhao L, Xu H. Circular RNA hsa_circ_0000515 acts as a miR-326 sponge to promote cervical cancer progression through up-regulation of ELK1. Aging. 2019;11(22):9982–99.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Tang W, Fu K, Sun H, Rong D, Wang H, Cao H. CircRNA microarray profiling identifies a novel circulating biomarker for detection of gastric cancer. Mol Cancer. 2018;17(1):1–6.CrossRef Tang W, Fu K, Sun H, Rong D, Wang H, Cao H. CircRNA microarray profiling identifies a novel circulating biomarker for detection of gastric cancer. Mol Cancer. 2018;17(1):1–6.CrossRef
47.
48.
Zurück zum Zitat Ma X-K, Wang M-R, Liu C-X, Dong R, Carmichael GG, Chen L-L, et al. CIRCexplorer3: a CLEAR pipeline for direct comparison of circular and linear RNA expression. Genom Proteom Bioinform. 2019;17(5):511–21.CrossRef Ma X-K, Wang M-R, Liu C-X, Dong R, Carmichael GG, Chen L-L, et al. CIRCexplorer3: a CLEAR pipeline for direct comparison of circular and linear RNA expression. Genom Proteom Bioinform. 2019;17(5):511–21.CrossRef
49.
Zurück zum Zitat Karthik L, Kumar G, Keswani T, Bhattacharyya A, Chandar SS, Bhaskara RK. Protease inhibitors from marine actinobacteria as a potential source for antimalarial compound. PLoS ONE. 2014;9(3):e90972.PubMedPubMedCentralCrossRef Karthik L, Kumar G, Keswani T, Bhattacharyya A, Chandar SS, Bhaskara RK. Protease inhibitors from marine actinobacteria as a potential source for antimalarial compound. PLoS ONE. 2014;9(3):e90972.PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Liu B, Li J, Cairns MJ. Identifying miRNAs, targets and functions. Brief Bioinform. 2014;15(1):1–19.PubMedCrossRef Liu B, Li J, Cairns MJ. Identifying miRNAs, targets and functions. Brief Bioinform. 2014;15(1):1–19.PubMedCrossRef
51.
Zurück zum Zitat Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.PubMedCrossRef Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.PubMedCrossRef
52.
Zurück zum Zitat Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384–8.PubMedCrossRef Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384–8.PubMedCrossRef
53.
Zurück zum Zitat Kristensen LS, Andersen MS, Stagsted LV, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675–91.PubMedCrossRef Kristensen LS, Andersen MS, Stagsted LV, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675–91.PubMedCrossRef
54.
Zurück zum Zitat Mao W, Wang K, Xu B, Zhang H, Sun S, Hu Q, et al. ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma. Mol Cancer. 2021;20(1):1–7. Mao W, Wang K, Xu B, Zhang H, Sun S, Hu Q, et al. ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma. Mol Cancer. 2021;20(1):1–7.
55.
Zurück zum Zitat Wang K, Sun Y, Tao W, Fei X, Chang C. Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals. Cancer Lett. 2017;394:1–12.PubMedCrossRef Wang K, Sun Y, Tao W, Fei X, Chang C. Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals. Cancer Lett. 2017;394:1–12.PubMedCrossRef
56.
Zurück zum Zitat Liu G, Huang K, Jie Z, Wu Y, Chen J, Chen Z, et al. CircFAT1 sponges miR-375 to promote the expression of Yes-associated protein 1 in osteosarcoma cells. Mol Cancer. 2018;17:1–16.CrossRef Liu G, Huang K, Jie Z, Wu Y, Chen J, Chen Z, et al. CircFAT1 sponges miR-375 to promote the expression of Yes-associated protein 1 in osteosarcoma cells. Mol Cancer. 2018;17:1–16.CrossRef
57.
Zurück zum Zitat Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015;22(3):256–64.PubMedCrossRef Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015;22(3):256–64.PubMedCrossRef
58.
Zurück zum Zitat Ding L, Zhao Y, Dang S, Wang Y, Li X, Yu X, et al. Circular RNA circ-DONSON facilitates gastric cancer growth and invasion via NURF complex dependent activation of transcription factor SOX4. Mol Cancer. 2019;18:1–11.CrossRef Ding L, Zhao Y, Dang S, Wang Y, Li X, Yu X, et al. Circular RNA circ-DONSON facilitates gastric cancer growth and invasion via NURF complex dependent activation of transcription factor SOX4. Mol Cancer. 2019;18:1–11.CrossRef
59.
Zurück zum Zitat Wang L, Long H, Zheng Q, Bo X, Xiao X, Li B. Circular RNA circRHOT1 promotes hepatocellular carcinoma progression by initiation of NR2F6 expression. Mol Cancer. 2019;18(1):1–12.PubMedPubMedCentralCrossRef Wang L, Long H, Zheng Q, Bo X, Xiao X, Li B. Circular RNA circRHOT1 promotes hepatocellular carcinoma progression by initiation of NR2F6 expression. Mol Cancer. 2019;18(1):1–12.PubMedPubMedCentralCrossRef
60.
Zurück zum Zitat Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56(1):55–66.PubMedCrossRef Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56(1):55–66.PubMedCrossRef
61.
Zurück zum Zitat You X, Vlatkovic I, Babic A, Will T, Epstein I, Tushev G, et al. Neural circular RNAs are derived from synaptic genes and regulated by development and plasticity. Nat Neurosci. 2015;18(4):603–10.PubMedPubMedCentralCrossRef You X, Vlatkovic I, Babic A, Will T, Epstein I, Tushev G, et al. Neural circular RNAs are derived from synaptic genes and regulated by development and plasticity. Nat Neurosci. 2015;18(4):603–10.PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat Du WW, Yang W, Liu E, Yang Z, Dhaliwal P, Yang BB. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res. 2016;44(6):2846–58.PubMedPubMedCentralCrossRef Du WW, Yang W, Liu E, Yang Z, Dhaliwal P, Yang BB. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res. 2016;44(6):2846–58.PubMedPubMedCentralCrossRef
63.
Zurück zum Zitat Zhou B, Yu J-W. A novel identified circular RNA, circRNA_010567, promotes myocardial fibrosis via suppressing miR-141 by targeting TGF-β1. Biochem Biophys Res Commun. 2017;487(4):769–75.PubMedCrossRef Zhou B, Yu J-W. A novel identified circular RNA, circRNA_010567, promotes myocardial fibrosis via suppressing miR-141 by targeting TGF-β1. Biochem Biophys Res Commun. 2017;487(4):769–75.PubMedCrossRef
64.
Zurück zum Zitat Fontemaggi G, Turco C, Esposito G, Di Agostino S. New molecular mechanisms and clinical impact of circRNAs in human cancer. Cancers. 2021;13(13):3154.PubMedPubMedCentralCrossRef Fontemaggi G, Turco C, Esposito G, Di Agostino S. New molecular mechanisms and clinical impact of circRNAs in human cancer. Cancers. 2021;13(13):3154.PubMedPubMedCentralCrossRef
66.
Zurück zum Zitat Vickers NJ. Animal communication: when i’m calling you, will you answer too? Curr Biol. 2017;27(14):R713–5.PubMedCrossRef Vickers NJ. Animal communication: when i’m calling you, will you answer too? Curr Biol. 2017;27(14):R713–5.PubMedCrossRef
67.
Zurück zum Zitat Zhang M, Huang N, Yang X, Luo J, Yan S, Xiao F, et al. A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis. Oncogene. 2018;37(13):1805–14.PubMedCrossRef Zhang M, Huang N, Yang X, Luo J, Yan S, Xiao F, et al. A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis. Oncogene. 2018;37(13):1805–14.PubMedCrossRef
68.
Zurück zum Zitat Huang Z, Ding Y, Zhang L, He S, Jia Z, Gu C, et al. Upregulated circPDK1 promotes RCC cell migration and invasion by regulating the miR-377-3P-NOTCH1 Axis in renal cell carcinoma. Onco Targets Ther. 2020;13:11237.PubMedPubMedCentralCrossRef Huang Z, Ding Y, Zhang L, He S, Jia Z, Gu C, et al. Upregulated circPDK1 promotes RCC cell migration and invasion by regulating the miR-377-3P-NOTCH1 Axis in renal cell carcinoma. Onco Targets Ther. 2020;13:11237.PubMedPubMedCentralCrossRef
69.
Zurück zum Zitat Luo S, Deng F, Yao N, Zheng F. Circ_0005875 sponges miR-502-5p to promote renal cell carcinoma progression through upregulating E26 transformation specific-1. Anticancer Drugs. 2022;33(1):e286–98.PubMedCrossRef Luo S, Deng F, Yao N, Zheng F. Circ_0005875 sponges miR-502-5p to promote renal cell carcinoma progression through upregulating E26 transformation specific-1. Anticancer Drugs. 2022;33(1):e286–98.PubMedCrossRef
70.
Zurück zum Zitat Gong L-J, Wang XY, Yao X-d, Wu X, Gu W-Y. CircESRP1 inhibits clear cell renal cell carcinoma progression through the CTCF-mediated positive feedback loop. Cell Death Dis. 2021;12(11):1081.PubMedPubMedCentralCrossRef Gong L-J, Wang XY, Yao X-d, Wu X, Gu W-Y. CircESRP1 inhibits clear cell renal cell carcinoma progression through the CTCF-mediated positive feedback loop. Cell Death Dis. 2021;12(11):1081.PubMedPubMedCentralCrossRef
71.
Zurück zum Zitat Gui C-P, Liao B, Luo C-G, Chen Y-H, Tan L, Tang Y-M, et al. circCHST15 is a novel prognostic biomarker that promotes clear cell renal cell carcinoma cell proliferation and metastasis through the miR-125a-5p/EIF4EBP1 axis. Mol Cancer. 2021;20(1):169.PubMedPubMedCentralCrossRef Gui C-P, Liao B, Luo C-G, Chen Y-H, Tan L, Tang Y-M, et al. circCHST15 is a novel prognostic biomarker that promotes clear cell renal cell carcinoma cell proliferation and metastasis through the miR-125a-5p/EIF4EBP1 axis. Mol Cancer. 2021;20(1):169.PubMedPubMedCentralCrossRef
72.
Zurück zum Zitat Cen J, Liang Y, Huang Y, Pan Y, Shu G, Zheng Z, et al. Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis. Mol Cancer. 2021;20:1–14.CrossRef Cen J, Liang Y, Huang Y, Pan Y, Shu G, Zheng Z, et al. Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis. Mol Cancer. 2021;20:1–14.CrossRef
73.
Zurück zum Zitat Li J, Huang C, Zou Y, Ye J, Yu J, Gui Y. CircTLK1 promotes the proliferation and metastasis of renal cell carcinoma by sponging miR-136-5p. Mol Cancer. 2020;19(1):1–17.PubMedPubMedCentralCrossRef Li J, Huang C, Zou Y, Ye J, Yu J, Gui Y. CircTLK1 promotes the proliferation and metastasis of renal cell carcinoma by sponging miR-136-5p. Mol Cancer. 2020;19(1):1–17.PubMedPubMedCentralCrossRef
74.
Zurück zum Zitat Li K, Wan C-L, Guo Y. Circular RNA circMTO1 suppresses RCC cancer cell progression via miR9/LMX1A axis. Technol Cancer Res Treat. 2020;19:1533033820914286.PubMedPubMedCentralCrossRef Li K, Wan C-L, Guo Y. Circular RNA circMTO1 suppresses RCC cancer cell progression via miR9/LMX1A axis. Technol Cancer Res Treat. 2020;19:1533033820914286.PubMedPubMedCentralCrossRef
75.
Zurück zum Zitat Sun J, Yin A, Zhang W, Lv J, Liang Y, Li H, et al. CircUBAP2 inhibits proliferation and metastasis of clear cell renal cell carcinoma via targeting miR-148a-3p/FOXK2 pathway. Cell Transplant. 2020;29:0963689720925751.PubMedPubMedCentralCrossRef Sun J, Yin A, Zhang W, Lv J, Liang Y, Li H, et al. CircUBAP2 inhibits proliferation and metastasis of clear cell renal cell carcinoma via targeting miR-148a-3p/FOXK2 pathway. Cell Transplant. 2020;29:0963689720925751.PubMedPubMedCentralCrossRef
76.
Zurück zum Zitat Sun J, Pan S, Cui H, Li H. CircRNA SCARB1 promotes renal cell carcinoma progression via miR-510-5p/SDC3 axis. Curr Cancer Drug Targets. 2020;20(6):461–70.PubMedCrossRef Sun J, Pan S, Cui H, Li H. CircRNA SCARB1 promotes renal cell carcinoma progression via miR-510-5p/SDC3 axis. Curr Cancer Drug Targets. 2020;20(6):461–70.PubMedCrossRef
77.
Zurück zum Zitat Chen L, Wu D, Ding T. Circular RNA circ_0001368 inhibited growth and invasion in renal cell carcinoma by sponging miR-492 and targeting LATS2. Gene. 2020;753:144781.PubMedCrossRef Chen L, Wu D, Ding T. Circular RNA circ_0001368 inhibited growth and invasion in renal cell carcinoma by sponging miR-492 and targeting LATS2. Gene. 2020;753:144781.PubMedCrossRef
78.
Zurück zum Zitat Chen Q, Liu T, Bao Y, Zhao T, Wang J, Wang H, et al. CircRNA cRAPGEF5 inhibits the growth and metastasis of renal cell carcinoma via the miR-27a-3p/TXNIP pathway. Cancer Lett. 2020;469:68–77.PubMedCrossRef Chen Q, Liu T, Bao Y, Zhao T, Wang J, Wang H, et al. CircRNA cRAPGEF5 inhibits the growth and metastasis of renal cell carcinoma via the miR-27a-3p/TXNIP pathway. Cancer Lett. 2020;469:68–77.PubMedCrossRef
79.
Zurück zum Zitat Zhang G, Wang J, Tan W, Han X, Han B, Wang H, et al. Circular RNA EGLN3 silencing represses renal cell carcinoma progression through the miR-1224-3p/HMGXB3 axis. Acta Histochem. 2021;123(6):151752.PubMedCrossRef Zhang G, Wang J, Tan W, Han X, Han B, Wang H, et al. Circular RNA EGLN3 silencing represses renal cell carcinoma progression through the miR-1224-3p/HMGXB3 axis. Acta Histochem. 2021;123(6):151752.PubMedCrossRef
80.
Zurück zum Zitat Zhang D, Yang X-J, Luo Q-D, Fu D-L, Li Z-L, Zhang P, et al. Down-regulation of circular RNA_000926 attenuates renal cell carcinoma progression through miRNA-411–dependent CDH2 inhibition. Am J Pathol. 2019;189(12):2469–86.PubMedCrossRef Zhang D, Yang X-J, Luo Q-D, Fu D-L, Li Z-L, Zhang P, et al. Down-regulation of circular RNA_000926 attenuates renal cell carcinoma progression through miRNA-411–dependent CDH2 inhibition. Am J Pathol. 2019;189(12):2469–86.PubMedCrossRef
81.
Zurück zum Zitat Xue D, Wang H, Chen Y, Shen D, Lu J, Wang M, et al. Circ-AKT3 inhibits clear cell renal cell carcinoma metastasis via altering miR-296-3p/E-cadherin signals. Mol Cancer. 2019;18:1–13.CrossRef Xue D, Wang H, Chen Y, Shen D, Lu J, Wang M, et al. Circ-AKT3 inhibits clear cell renal cell carcinoma metastasis via altering miR-296-3p/E-cadherin signals. Mol Cancer. 2019;18:1–13.CrossRef
82.
Zurück zum Zitat Liu Z, Wang R, Zhu G. Circ_0035483 functions as a tumor promoter in renal cell carcinoma via the miR-31–5p-mediated HMGA1 upregulation. Cancer Manag Res. 2021;13:693–706.PubMedPubMedCentralCrossRef Liu Z, Wang R, Zhu G. Circ_0035483 functions as a tumor promoter in renal cell carcinoma via the miR-31–5p-mediated HMGA1 upregulation. Cancer Manag Res. 2021;13:693–706.PubMedPubMedCentralCrossRef
83.
Zurück zum Zitat Fang L, Ye T, An Y. Circular RNA FOXP1 induced by ZNF263 upregulates U2AF2 expression to accelerate renal cell carcinoma tumorigenesis and warburg effect through Sponging miR-423–5p. J Immunol Res. 2021;2021:1–16. Fang L, Ye T, An Y. Circular RNA FOXP1 induced by ZNF263 upregulates U2AF2 expression to accelerate renal cell carcinoma tumorigenesis and warburg effect through Sponging miR-423–5p. J Immunol Res. 2021;2021:1–16.
84.
Zurück zum Zitat Pei L, Lv X, Jia G, Tan X, Li M, Zhang A. Silencing circular RNA circ_0054537 and upregulating microRNA-640 suppress malignant progression of renal cell carcinoma via regulating neuronal pentraxin-2 (NPTX2). Bioengineered. 2021;12(1):8279–95.PubMedPubMedCentralCrossRef Pei L, Lv X, Jia G, Tan X, Li M, Zhang A. Silencing circular RNA circ_0054537 and upregulating microRNA-640 suppress malignant progression of renal cell carcinoma via regulating neuronal pentraxin-2 (NPTX2). Bioengineered. 2021;12(1):8279–95.PubMedPubMedCentralCrossRef
85.
Zurück zum Zitat Yang L, Wang L, Wu J, Wang Y. Circ_0000069 contributes to the growth, metastasis and glutamine metabolism in renal cell carcinoma (RCC) via regulating miR-125a-5p-dependent SLC1A5 expression. Transpl Immunol. 2023;77:101764.PubMedCrossRef Yang L, Wang L, Wu J, Wang Y. Circ_0000069 contributes to the growth, metastasis and glutamine metabolism in renal cell carcinoma (RCC) via regulating miR-125a-5p-dependent SLC1A5 expression. Transpl Immunol. 2023;77:101764.PubMedCrossRef
86.
Zurück zum Zitat Wang Y, Zhang Y, Su X, Qiu Q, Yuan Y, Weng C, et al. Circular RNA circDVL1 inhibits clear cell renal cell carcinoma progression through the miR-412-3p/PCDH7 axis. Int J Biol Sci. 2022;18(4):1491.PubMedPubMedCentralCrossRef Wang Y, Zhang Y, Su X, Qiu Q, Yuan Y, Weng C, et al. Circular RNA circDVL1 inhibits clear cell renal cell carcinoma progression through the miR-412-3p/PCDH7 axis. Int J Biol Sci. 2022;18(4):1491.PubMedPubMedCentralCrossRef
88.
Zurück zum Zitat Xie X, Li H, Gao C, Lai Y, Liang J, Chen Z, et al. Downregulation of Circular RNA circPSD3 promotes metastasis by modulating FBXW7 expression in clear cell renal cell carcinoma. Journal of Oncology. 2022;2022:1–18. Xie X, Li H, Gao C, Lai Y, Liang J, Chen Z, et al. Downregulation of Circular RNA circPSD3 promotes metastasis by modulating FBXW7 expression in clear cell renal cell carcinoma. Journal of Oncology. 2022;2022:1–18.
89.
Zurück zum Zitat Li J, Huang C, Zou Y, Yu J, Gui Y. Circular RNA MYLK promotes tumour growth and metastasis via modulating miR-513a-5p/VEGFC signalling in renal cell carcinoma. J Cell Mol Med. 2020;24(12):6609–21.PubMedPubMedCentralCrossRef Li J, Huang C, Zou Y, Yu J, Gui Y. Circular RNA MYLK promotes tumour growth and metastasis via modulating miR-513a-5p/VEGFC signalling in renal cell carcinoma. J Cell Mol Med. 2020;24(12):6609–21.PubMedPubMedCentralCrossRef
90.
Zurück zum Zitat Yang C-Y, Wang J, Zhang J-Q, Cai H-m. Human circular RNA hsa_circRNA_101705 (circTXNDC11) regulates renal cancer progression by regulating MAPK/ERK pathway. Bioengineered. 2021;12(1):4432–41.PubMedPubMedCentralCrossRef Yang C-Y, Wang J, Zhang J-Q, Cai H-m. Human circular RNA hsa_circRNA_101705 (circTXNDC11) regulates renal cancer progression by regulating MAPK/ERK pathway. Bioengineered. 2021;12(1):4432–41.PubMedPubMedCentralCrossRef
91.
Zurück zum Zitat Li R, Luo S, Zhang D. Circular RNA hsa_circ_0054537 sponges miR-130a-3p to promote the progression of renal cell carcinoma through regulating cMet pathway. Gene. 2020;754:144811.PubMedCrossRef Li R, Luo S, Zhang D. Circular RNA hsa_circ_0054537 sponges miR-130a-3p to promote the progression of renal cell carcinoma through regulating cMet pathway. Gene. 2020;754:144811.PubMedCrossRef
92.
Zurück zum Zitat Lin L, Cai J. Circular RNA circ-EGLN3 promotes renal cell carcinoma proliferation and aggressiveness via miR-1299-mediated IRF7 activation. J Cell Biochem. 2020;121(11):4377–85.PubMedCrossRef Lin L, Cai J. Circular RNA circ-EGLN3 promotes renal cell carcinoma proliferation and aggressiveness via miR-1299-mediated IRF7 activation. J Cell Biochem. 2020;121(11):4377–85.PubMedCrossRef
93.
Zurück zum Zitat Zeng J, Feng Q, Wang Y, Xie G, Li Y, Yang Y, et al. Circular RNA circ_001842 plays an oncogenic role in renal cell carcinoma by disrupting microRNA-502-5p-mediated inhibition of SLC39A14. J Cell Mol Med. 2020;24(17):9712–25.PubMedPubMedCentralCrossRef Zeng J, Feng Q, Wang Y, Xie G, Li Y, Yang Y, et al. Circular RNA circ_001842 plays an oncogenic role in renal cell carcinoma by disrupting microRNA-502-5p-mediated inhibition of SLC39A14. J Cell Mol Med. 2020;24(17):9712–25.PubMedPubMedCentralCrossRef
94.
Zurück zum Zitat Yu R, Yao J, Ren Y. A novel circRNA, circNUP98, a potential biomarker, acted as an oncogene via the miR-567/PRDX3 axis in renal cell carcinoma. J Cell Mol Med. 2020;24(17):10177–88.PubMedPubMedCentralCrossRef Yu R, Yao J, Ren Y. A novel circRNA, circNUP98, a potential biomarker, acted as an oncogene via the miR-567/PRDX3 axis in renal cell carcinoma. J Cell Mol Med. 2020;24(17):10177–88.PubMedPubMedCentralCrossRef
95.
Zurück zum Zitat Wang G, Xue W, Jian W, Liu P, Wang Z, Wang C, et al. The effect of Hsa_circ_0001451 in clear cell renal cell carcinoma cells and its relationship with clinicopathological features. J Cancer. 2018;9(18):3269.PubMedPubMedCentralCrossRef Wang G, Xue W, Jian W, Liu P, Wang Z, Wang C, et al. The effect of Hsa_circ_0001451 in clear cell renal cell carcinoma cells and its relationship with clinicopathological features. J Cancer. 2018;9(18):3269.PubMedPubMedCentralCrossRef
96.
Zurück zum Zitat Han B, Shaolong E, Luan L, Li N, Liu X. CircHIPK3 promotes clear cell renal cell carcinoma (ccRCC) cells proliferation and metastasis via altering of miR-508-3p/CXCL13 signal. Onco Targets Ther. 2020;13:6051.PubMedPubMedCentralCrossRef Han B, Shaolong E, Luan L, Li N, Liu X. CircHIPK3 promotes clear cell renal cell carcinoma (ccRCC) cells proliferation and metastasis via altering of miR-508-3p/CXCL13 signal. Onco Targets Ther. 2020;13:6051.PubMedPubMedCentralCrossRef
97.
Zurück zum Zitat Franz A, Ralla B, Weickmann S, Jung M, Rochow H, Stephan C, et al. Circular RNAs in clear cell renal cell carcinoma: their microarray-based identification, analytical validation, and potential use in a clinico-genomic model to improve prognostic accuracy. Cancers. 2019;11(10):1473.PubMedPubMedCentralCrossRef Franz A, Ralla B, Weickmann S, Jung M, Rochow H, Stephan C, et al. Circular RNAs in clear cell renal cell carcinoma: their microarray-based identification, analytical validation, and potential use in a clinico-genomic model to improve prognostic accuracy. Cancers. 2019;11(10):1473.PubMedPubMedCentralCrossRef
98.
Zurück zum Zitat Rashedi S, Mardani M, Rafati A, Khavandi MM, Mohammadi F, Javanshir S, et al. Circular RNAs as prognostic and diagnostic biomarkers in renal cell carcinoma. J Clin Lab Anal. 2022;36(10):e24670.PubMedPubMedCentralCrossRef Rashedi S, Mardani M, Rafati A, Khavandi MM, Mohammadi F, Javanshir S, et al. Circular RNAs as prognostic and diagnostic biomarkers in renal cell carcinoma. J Clin Lab Anal. 2022;36(10):e24670.PubMedPubMedCentralCrossRef
99.
Zurück zum Zitat Li W, Yang F-Q, Sun C-M, Huang J-H, Zhang H-M, Li X, et al. circPRRC2A promotes angiogenesis and metastasis through epithelial-mesenchymal transition and upregulates TRPM3 in renal cell carcinoma. Theranostics. 2020;10(10):4395.PubMedPubMedCentralCrossRef Li W, Yang F-Q, Sun C-M, Huang J-H, Zhang H-M, Li X, et al. circPRRC2A promotes angiogenesis and metastasis through epithelial-mesenchymal transition and upregulates TRPM3 in renal cell carcinoma. Theranostics. 2020;10(10):4395.PubMedPubMedCentralCrossRef
100.
Zurück zum Zitat Liu G, Zhou J, Piao Y, Zhao X, Zuo Y, Ji Z. Hsa_circ_0085576 promotes clear cell renal cell carcinoma tumorigenesis and metastasis through the miR-498/YAP1 axis. Aging. 2020;12(12):11530.PubMedPubMedCentralCrossRef Liu G, Zhou J, Piao Y, Zhao X, Zuo Y, Ji Z. Hsa_circ_0085576 promotes clear cell renal cell carcinoma tumorigenesis and metastasis through the miR-498/YAP1 axis. Aging. 2020;12(12):11530.PubMedPubMedCentralCrossRef
101.
Zurück zum Zitat Frey L, Klümper N, Schmidt D, Kristiansen G, Toma M, Ritter M, et al. CircEHD2, CircNETO2 and CircEGLN3 as diagnostic and prognostic biomarkers for patients with renal cell carcinoma. Cancers. 2021;13(9):2177.PubMedPubMedCentralCrossRef Frey L, Klümper N, Schmidt D, Kristiansen G, Toma M, Ritter M, et al. CircEHD2, CircNETO2 and CircEGLN3 as diagnostic and prognostic biomarkers for patients with renal cell carcinoma. Cancers. 2021;13(9):2177.PubMedPubMedCentralCrossRef
102.
Zurück zum Zitat Huang Y, Zhang Y, Jia L, Liu C, Xu F. Circular RNA ABCB10 promotes tumor progression and correlates with pejorative prognosis in clear cell renal cell carcinoma. Int J Biol Markers. 2019;34(2):176–83.PubMedCrossRef Huang Y, Zhang Y, Jia L, Liu C, Xu F. Circular RNA ABCB10 promotes tumor progression and correlates with pejorative prognosis in clear cell renal cell carcinoma. Int J Biol Markers. 2019;34(2):176–83.PubMedCrossRef
103.
Zurück zum Zitat He T, Zhang Q, Xu P, Tao W, Lin F, Liu R, et al. Extracellular vesicle-circEHD2 promotes the progression of renal cell carcinoma by activating cancer-associated fibroblasts. Mol Cancer. 2023;22(1):117.PubMedPubMedCentralCrossRef He T, Zhang Q, Xu P, Tao W, Lin F, Liu R, et al. Extracellular vesicle-circEHD2 promotes the progression of renal cell carcinoma by activating cancer-associated fibroblasts. Mol Cancer. 2023;22(1):117.PubMedPubMedCentralCrossRef
104.
Zurück zum Zitat Herculano-Houzel S. The human brain in numbers: a linearly scaled-up primate brain. Front Human Neurosci. 2009;3:31.CrossRef Herculano-Houzel S. The human brain in numbers: a linearly scaled-up primate brain. Front Human Neurosci. 2009;3:31.CrossRef
105.
Zurück zum Zitat Osenberg S, Paz Yaacov N, Safran M, Moshkovitz S, Shtrichman R, Sherf O, et al. Alu sequences in undifferentiated human embryonic stem cells display high levels of A-to-I RNA editing. PLoS ONE. 2010;5(6):e11173.PubMedPubMedCentralCrossRef Osenberg S, Paz Yaacov N, Safran M, Moshkovitz S, Shtrichman R, Sherf O, et al. Alu sequences in undifferentiated human embryonic stem cells display high levels of A-to-I RNA editing. PLoS ONE. 2010;5(6):e11173.PubMedPubMedCentralCrossRef
106.
Zurück zum Zitat Di Timoteo G, Rossi F, Bozzoni I. Circular RNAs in cell differentiation and development. Development. 2020;147(16):dev182725.PubMedCrossRef Di Timoteo G, Rossi F, Bozzoni I. Circular RNAs in cell differentiation and development. Development. 2020;147(16):dev182725.PubMedCrossRef
108.
Zurück zum Zitat Huang K-B, Pan Y-H, Shu G-N, Yao H-H, Liu X, Zhou M, et al. Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184/GPCPD1/lysophosphatidic acid axis. Cancer Lett. 2021;523:121–34.PubMedCrossRef Huang K-B, Pan Y-H, Shu G-N, Yao H-H, Liu X, Zhou M, et al. Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184/GPCPD1/lysophosphatidic acid axis. Cancer Lett. 2021;523:121–34.PubMedCrossRef
109.
Zurück zum Zitat Zhang M-x, Wang J-l, Mo C-q, Mao X-p, Feng Z-h, Li J-y, et al. CircME1 promotes aerobic glycolysis and sunitinib resistance of clear cell renal cell carcinoma through cis-regulation of ME1. Oncogene. 2022;41(33):3979–90.PubMedPubMedCentralCrossRef Zhang M-x, Wang J-l, Mo C-q, Mao X-p, Feng Z-h, Li J-y, et al. CircME1 promotes aerobic glycolysis and sunitinib resistance of clear cell renal cell carcinoma through cis-regulation of ME1. Oncogene. 2022;41(33):3979–90.PubMedPubMedCentralCrossRef
110.
Zurück zum Zitat Yan L, Liu G, Cao H, Zhang H, Shao F. Hsa_circ_0035483 sponges hsa-miR-335 to promote the gemcitabine-resistance of human renal cancer cells by autophagy regulation. Biochem Biophys Res Commun. 2019;519(1):172–8.PubMedCrossRef Yan L, Liu G, Cao H, Zhang H, Shao F. Hsa_circ_0035483 sponges hsa-miR-335 to promote the gemcitabine-resistance of human renal cancer cells by autophagy regulation. Biochem Biophys Res Commun. 2019;519(1):172–8.PubMedCrossRef
111.
Zurück zum Zitat Harries LW, Hernandez D, Henley W, Wood AR, Holly AC, Bradley-Smith RM, et al. Human aging is characterized by focused changes in gene expression and deregulation of alternative splicing. Aging Cell. 2011;10(5):868–78.PubMedCrossRef Harries LW, Hernandez D, Henley W, Wood AR, Holly AC, Bradley-Smith RM, et al. Human aging is characterized by focused changes in gene expression and deregulation of alternative splicing. Aging Cell. 2011;10(5):868–78.PubMedCrossRef
112.
Zurück zum Zitat Schneider T, Schreiner S, Preußer C, Bindereif A, Rossbach O. Northern blot analysis of circular RNAs. Circular RNAs: Methods Protoc. 2018;1724:119–33.CrossRef Schneider T, Schreiner S, Preußer C, Bindereif A, Rossbach O. Northern blot analysis of circular RNAs. Circular RNAs: Methods Protoc. 2018;1724:119–33.CrossRef
113.
Zurück zum Zitat Zhou T, Xie X, Li M, Shi J, Zhou JJ, Knox KS, et al. Rat BodyMap transcriptomes reveal unique circular RNA features across tissue types and developmental stages. RNA. 2018;24(11):1443–56.PubMedPubMedCentralCrossRef Zhou T, Xie X, Li M, Shi J, Zhou JJ, Knox KS, et al. Rat BodyMap transcriptomes reveal unique circular RNA features across tissue types and developmental stages. RNA. 2018;24(11):1443–56.PubMedPubMedCentralCrossRef
114.
Zurück zum Zitat Wawrzyniak O, Zarębska Ż, Kuczyński K, Gotz-Więckowska A, Rolle K. Protein-related circular RNAs in human pathologies. Cells. 2020;9(8):1841.PubMedPubMedCentralCrossRef Wawrzyniak O, Zarębska Ż, Kuczyński K, Gotz-Więckowska A, Rolle K. Protein-related circular RNAs in human pathologies. Cells. 2020;9(8):1841.PubMedPubMedCentralCrossRef
115.
Zurück zum Zitat Du WW, Yang W, Li X, Awan FM, Yang Z, Fang L, et al. A circular RNA circ-DNMT1 enhances breast cancer progression by activating autophagy. Oncogene. 2018;37(44):5829–42.PubMedCrossRef Du WW, Yang W, Li X, Awan FM, Yang Z, Fang L, et al. A circular RNA circ-DNMT1 enhances breast cancer progression by activating autophagy. Oncogene. 2018;37(44):5829–42.PubMedCrossRef
116.
Zurück zum Zitat Fang L, Du WW, Awan FM, Dong J, Yang BB. The circular RNA circ-Ccnb1 dissociates Ccnb1/Cdk1 complex suppressing cell invasion and tumorigenesis. Cancer Lett. 2019;459:216–26.PubMedCrossRef Fang L, Du WW, Awan FM, Dong J, Yang BB. The circular RNA circ-Ccnb1 dissociates Ccnb1/Cdk1 complex suppressing cell invasion and tumorigenesis. Cancer Lett. 2019;459:216–26.PubMedCrossRef
117.
Zurück zum Zitat Schultz N, Marenstein DR, De Angelis DA, Wang W-Q, Nelander S, Jacobsen A, et al. Off-target effects dominate a large-scale RNAi screen for modulators of the TGF-β pathway and reveal microRNA regulation of TGFBR2. Silence. 2011;2(1):1–20.CrossRef Schultz N, Marenstein DR, De Angelis DA, Wang W-Q, Nelander S, Jacobsen A, et al. Off-target effects dominate a large-scale RNAi screen for modulators of the TGF-β pathway and reveal microRNA regulation of TGFBR2. Silence. 2011;2(1):1–20.CrossRef
118.
Zurück zum Zitat Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, et al. Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA. 2006;12(7):1179–87.PubMedPubMedCentralCrossRef Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, et al. Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA. 2006;12(7):1179–87.PubMedPubMedCentralCrossRef
119.
Zurück zum Zitat Setten RL, Rossi JJ, Han S-p. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421–46.PubMedCrossRef Setten RL, Rossi JJ, Han S-p. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421–46.PubMedCrossRef
120.
Zurück zum Zitat Dancy JG, Wadajkar AS, Connolly NP, Galisteo R, Ames HM, Peng S, et al. Decreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast cancer. Sci Adv. 2020;6(3):eaax3931.PubMedPubMedCentralCrossRef Dancy JG, Wadajkar AS, Connolly NP, Galisteo R, Ames HM, Peng S, et al. Decreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast cancer. Sci Adv. 2020;6(3):eaax3931.PubMedPubMedCentralCrossRef
121.
Zurück zum Zitat Jia Y-P, Ma B-Y, Wei X-W, Qian Z-Y. The in vitro and in vivo toxicity of gold nanoparticles. Chin Chem Lett. 2017;28(4):691–702.CrossRef Jia Y-P, Ma B-Y, Wei X-W, Qian Z-Y. The in vitro and in vivo toxicity of gold nanoparticles. Chin Chem Lett. 2017;28(4):691–702.CrossRef
Metadaten
Titel
Circular RNAs in renal cell carcinoma: from mechanistic to clinical perspective
verfasst von
Chunjie Huang
Pooya Esfani Sarafraz
Parisa Enayati
Elham Mortazavi Mamaghani
Emad Babakhanzadeh
Majid Nazari
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
Cancer Cell International / Ausgabe 1/2023
Elektronische ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-023-03128-w

Weitere Artikel der Ausgabe 1/2023

Cancer Cell International 1/2023 Zur Ausgabe

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.